Novel imaging techniques in refractory pituitary adenomas

J MacFarlane; K A Huynh; A S Powlson; A G Kolias; R J Mannion; D J Scoffings; I A Mendichovszky; H K Cheow; W A Bashari; J Jones; D Gillett; O Koulouri; Mark Gurnell

doi:10.1007/s11102-023-01304-9

Novel imaging techniques in refractory pituitary adenomas

Pituitary. 2023 Jun;26(3):288-292. doi: 10.1007/s11102-023-01304-9. Epub 2023 Mar 27.

Authors

J MacFarlane¹, K A Huynh¹, A S Powlson¹, A G Kolias^{2

3}, R J Mannion³, D J Scoffings⁴, I A Mendichovszky^{5

6

4}, H K Cheow^{6

4}, W A Bashari¹, J Jones⁴, D Gillett^{1

6}, O Koulouri¹, Mark Gurnell⁷

Affiliations

¹ Cambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
² Department of Neurosurgery, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
³ Department of Neurosurgery, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
⁴ Department of Radiology, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
⁵ Department of Radiology, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
⁶ Department of Nuclear Medicine, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
⁷ Cambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, University of Cambridge and National Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK. mg299@medschl.cam.ac.uk.

Abstract

Accurate localization of the site(s) of active disease is key to informing decision-making in the management of refractory pituitary adenomas when autonomous hormone secretion and/or continued tumor growth challenge conventional therapeutic approaches. In this context, the use of non-standard MR sequences, alternative post-acquisition image processing, or molecular (functional) imaging may provide valuable additional information to inform patient management.

Keywords: MRI; Molecular / functional imaging; PET; Radiomics; Refractory pituitary adenoma.

Publication types

Review

MeSH terms

Adenoma* / pathology
Humans
Magnetic Resonance Imaging / methods
Pituitary Neoplasms* / pathology

Grants and funding

WT_/Wellcome Trust/United Kingdom